A Note from the Editor

As the holiday period approaches, we at Psychedelic Alpha are busy focusing on the launch of several new features and pieces of content to round out 2025 and welcome the new year.

There’s little rest among psychedelics advocates, too. Outside of the traditional model of pharmaceutical approvals, where a regulator like the FDA gives a nod to new drugs, some countries and states continue to pursue psychedelic access pathways with a focus on launching next year.

In Europe, tweaks to Czechia’s criminal code will allow for medical access to psilocybin in 2026, for certain patients in specific contexts, as guidelines for the use of the drug have now been drafted by the country’s psychiatric society.

In the U.S., meanwhile, New Mexico’s Medical Psilocybin Advisory Board has brought forward plans for the launch of its state-regulated program by a year. It now hopes to allow the first patients to access psilocybin in December 2026. That’s around the same time that a pharmaceutical form of psilocybin could be up for FDA approval. It’s certainly going to be an interesting year.

At the federal level, a rumoured executive order to reclassify marijuana has been making headlines. If the supposedly imminent move materialises, psychedelics advocates will be watching closely for how MAGA reacts.

And, back at Psychedelic Alpha, we were pleased to publish the second Issue of The Psychedelic Practitioner earlier this week, which focuses on the topic of Psychedelic Preparation. The next Issue, which will be published in February, will focus on Dosing.

Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelics business, policy, research and beyond.

Josh Hardman
Founder & Editor